Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics. (3rd April 2021)

• Record Type: Journal Article
• Authors: Mahmoudian, Mohammad; Valizadeh, Hadi; Löbenberg, Raimar; Zakeri-Milani, Parvin
• Is Part Of: Journal of microencapsulation. Volume 38:Number 3(2021)
• Page Start: 192
• Page End: 202
• Publication Date: 2021-04-03
• Subjects: Bortezomib -- liposomes -- solid lipid nanoparticles -- self-nanoemulsifying drug delivery systems -- formulation -- pharmacokinetics; Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.1080/02652048.2021.1876175
• Languages: English
• ISSNs: 0265-2048

Abstract

Abstract: Aim: Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Severe side effects of BTZ are the major dose-limiting factor. Particulate drug delivery systems for BTZ are polymeric and lipidic drug delivery systems. This review focussed on lipidic-nano drug delivery systems (LNDDSs) for the delivery of BTZ. Results: LNDDSs including liposomes, solid lipid nanoparticles, and self-nanoemulsifying drug delivery systems showed reduce systemic side effects, improved therapeutic efficacy, and increased intestinal absorption. Besides LNDDSs were used to target-delivery of BTZ to cancer. Conclusion: Overall, LNDDSs can be considered as a novel delivery system for BTZ to resolve the treatment-associated restrictions.